Latest Vertex Pharmaceuticals Inc. Stories

2014-06-24 12:27:59

CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process BETHESDA, Md., June 24, 2014 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation applauds the successful results of Phase 3 studies of ivacaftor (Kalydeco(TM)) in combination with lumacaftor (VX-809) for people with two copies of the F508del mutation of cystic fibrosis (CF). The results showed significant improvements in lung function and other key measures of the disease,...

2014-03-26 12:29:27

Editor Note: For more information about this release, please scroll to bottom. LONDON, March 26, 2014 /PRNewswire/ -- On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the...

2014-01-16 08:24:26

LONDON, January 16, 2014 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Wednesday, January 15, 2014, the US equity market posted gains. The S&P 500 closed the day 0.52% higher at 1,848.38; the Dow Jones Industrial Average finished 0.66% higher at 16,481.94; and the NASDAQ Composite ended 0.76% higher at 4,214.88. The S&P 500 Health Care Sector Index ended the day at 659.40, down 0.14%; while the same has gained...

2011-06-10 11:20:00

BETHESDA, Md., June 10, 2011 /PRNewswire-USNewswire/ -- Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA). Pending FDA review and approval, Vertex expects to open the program at clinical sites in the United States as early as July. "We are delighted that...

2011-05-23 14:00:00

Vertex Pharmaceuticals Inc.'s highly anticipated hepatitis C drug has finally won U.S. approval, which will usher in a new marketing battle with a rival medicine from Merck & Co. Incivek is poised to help transform treatment of hepatitis C by nearly doubling the chances of curing the serious liver disease.  Some industry analysts project Incivek sales will top $5 billion a year. The approval was widely expected after an FDA advisory panel unanimously recommended the drug last month....

2008-11-03 08:10:59

A meticulously watched hepatitis C drug, developed by Vertex Pharmaceuticals Inc, has a remarkable capability to stop the virus in patients in which other treatments were unsuccessful, and others not previously treated for the severe liver disease. Like previous studies, the experimental Vertex drug, telaprevir, when united with typical liver treatments, indicated the promise of cutting in half the 48 weeks of treatment required with the present set of care and has superior effectiveness. In...

Word of the Day
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.